Breakthrough Gene Therapy Enables Infant Born Deaf to Hear
By Physician’s Briefing Staff HealthDay Reporter
FRIDAY, May 10, 2024 -- Significant hearing improvements have been achieved in an infant with profound hearing loss due to a biallelic otoferlin gene (OTOF) mutation, according to the results of a first-in-human gene therapy trial presented at the annual meeting of the American Society of Gene & Cell Therapy, held from May 7 to 11 in Baltimore.
The gene therapy that the 10-month-old female infant with auditory neuropathy received involved the transmission into her right ear of a working copy of the OTOF gene, delivered during surgery into the ear's cochlea via a harmless virus called AAV1. The baby girl was also fitted out with a cochlear implant in her left ear. Six months later, she could respond to sound even when her left ear cochlear implant was switched off. She could even detect low sounds such as whispers in her treated right ear.
"These results are spectacular and better than I expected," Manohar Bance, M.B.,Ch.B., an ear surgeon at Cambridge University in the United Kingdom and chief investigator of the new trial, said in a statement. "Gene therapy has been the future in otology and audiology for many years and I'm so excited that it is now finally here. This is hopefully the start of a new era for gene therapies for the inner ear and many types of hearing loss."
The gene deficiency behind auditory neuropathy often goes undetected in newborn screenings, so children with the condition are often not diagnosed until age 2 or 3, when delays in speech have set in.
"We have a short time frame to intervene because of the rapid pace of brain development at this age," Bance said. "Delays in the diagnosis can also cause confusion for families as the many reasons for delayed speech and late intervention can impact children's development.”
The global trial is ongoing, and experts believe gene therapy could revolutionize the treatment of hearing loss.
The trial is sponsored by Regeneron.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Excellent Outcomes Seen for Radiofrequency Catheter Ablation for Paroxysmal A-Fib
WEDNESDAY, May 22, 2024 -- Clinical outcomes are excellent with use of radiofrequency (RF) catheter ablation (CA) for paroxysmal atrial fibrillation (PAF), according to a study...
Volume of Leisure-Time Physical Activity Not Tied to Coronary Artery Calcium
WEDNESDAY, May 22, 2024 -- Ongoing leisure-time physical activity, even at high volumes, is not associated with coronary artery calcium (CAC) progression, a marker of...
Metastatic Cancer Survival No Better at Practices With Higher NQF 0210 Rates
WEDNESDAY, May 22, 2024 -- For patients with metastatic or advanced cancer, treatment at practices with higher rates of National Quality Forum (NQF) 0210 (patients receiving...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.